Canada Spends Logo

Explore our Budget 2026 analysis

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Calgary

$120,000.00

Cross-kingdom interactions between airway Candida species, bacterial pathogens, and the host immune system in ventilator-associated pneumonia

FY 2025-26

Summary
Background: Ventilator-associated pneumonia (VAP) affects up to 40% of mechanically ventilated patients in Canadian intensive care units (ICU). VAP doubles mortality risk, prolongs hospital stays, and costs the healthcare system billions per year, yet its pathogenesis remains incompletely understood. VAP is a severe bacterial infection, but prior research has highlighted that when patients harbour Candida fungi in their lungs, they are at a higher risk for getting bacterial VAP. This raises a fundamental unanswered question about the cause of VAP: how does a non-infectious fungus contribute to bacterial pneumonia, and what should be done to treat it? Objective/Hypothesis: We hypothesize that airway Candida promote bacterial VAP by enhancing the virulence of neighboring bacteria in the lungs, and by disrupting host immune defenses. Methods: Studying tracheal aspirates from ventilated ICU patients, we use DNA sequencing and culturomics to characterize the bacteria and fungi, and to identify patients with Candida in their lungs. We use multi-omics methods to study the immune response in the airways of patients who have Candida in their lungs compared to those who do not. Results: To date, 230 samples from 97 patients have been collected, with the first 51 patients fully analyzed. Candida was detected in 53% samples at the time of ICU admission, and its presence correlated with increased incidence of VAP. Patients harbouring airway Candida also have higher levels of pneumonia-causing bacteria, like Staphylococcus aureus. Exposing airway epithelial cells to Candida plus VAP bacteria in vitro results in synergistic, increased cell damage compared to either organism alone. Conclusions: Candida colonization of the airways is common, and is associated with a higher risk of VAP and mortality. Our preliminary results support the hypothesis that Candida promotes bacterial VAP through cross-kingdom interactions with airway pathogens and the host immune system.
Program
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
559840
Name
Strayer Kathryn A
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Cross-kingdom interactions between airway Candida species, bacterial pathogens, and the host immune system in ventilator-associated pneumonia
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Critical Illness; Fungi; Hospital-Acquired Pneumonia; Host-Microbe Interactions; Immune-Microbe Interactions; Microbiome
Abstract
Background: Ventilator-associated pneumonia (VAP) affects up to 40% of mechanically ventilated patients in Canadian intensive care units (ICU). VAP doubles mortality risk, prolongs hospital stays, and costs the healthcare system billions per year, yet its pathogenesis remains incompletely understood. VAP is a severe bacterial infection, but prior research has highlighted that when patients harbour Candida fungi in their lungs, they are at a higher risk for getting bacterial VAP. This raises a fundamental unanswered question about the cause of VAP: how does a non-infectious fungus contribute to bacterial pneumonia, and what should be done to treat it? Objective/Hypothesis: We hypothesize that airway Candida promote bacterial VAP by enhancing the virulence of neighboring bacteria in the lungs, and by disrupting host immune defenses. Methods: Studying tracheal aspirates from ventilated ICU patients, we use DNA sequencing and culturomics to characterize the bacteria and fungi, and to identify patients with Candida in their lungs. We use multi-omics methods to study the immune response in the airways of patients who have Candida in their lungs compared to those who do not. Results: To date, 230 samples from 97 patients have been collected, with the first 51 patients fully analyzed. Candida was detected in 53% samples at the time of ICU admission, and its presence correlated with increased incidence of VAP. Patients harbouring airway Candida also have higher levels of pneumonia-causing bacteria, like Staphylococcus aureus. Exposing airway epithelial cells to Candida plus VAP bacteria in vitro results in synergistic, increased cell damage compared to either organism alone. Conclusions: Candida colonization of the airways is common, and is associated with a higher risk of VAP and mortality. Our preliminary results support the hypothesis that Candida promotes bacterial VAP through cross-kingdom interactions with airway pathogens and the host immune system.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Strayer, Kathryn A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~